Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
about
Targeted therapy for advanced renal cell carcinomaCosts of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignanciesMetastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumabIndirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.Antitumor activity of recombinant antimicrobial peptide penaeidin-2 against kidney cancer cells.Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.The allogeneic graft-versus-cancer effect.Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma.Bevacizumab: overview of the literature.Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis.Multiple metastatic deposits in the head and neck region from a renal cell carcinoma.The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment.Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.Second-line treatment for renal cell cancer.Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.SUN vs BEVthornIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival.Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib.Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.Orellanine specifically targets renal clear cell carcinoma.Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-Jun Activation in Renal Cell Carcinoma.Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis.The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma.
P2860
Q24242946-B191FEAF-4D5D-42C1-B8AC-A49C5F554665Q33387073-49881AC5-9A8D-44CD-9832-A3280695112BQ33590458-BFE8D27F-30AB-44D1-8FA1-06B85DFE977FQ33903747-DBEC40DE-B1EB-4E57-AFC7-AD28C4137672Q33960788-A2B363E8-13C6-4B81-9AFB-5176DE4ABCB4Q33976779-B355B640-ADF6-4CC9-8004-C5C0362BB57FQ34356881-1127050D-71E9-4303-A3BD-90B76F2398C5Q34417804-094A13BC-8889-4A4A-B0EF-FEA976E71D34Q35205445-907DC4BD-5AA5-480C-88DE-2A3C5758C631Q35227664-AE453D24-422D-49C6-9F94-71D7D9862A8FQ35934532-7D622B1F-D383-4092-A9E4-7E73BFFAA397Q37593125-4AF6BBAE-C9B2-4E00-862A-9FA8265F4519Q37768461-6C2FA33B-FC3B-4080-83C6-A70669E1B58EQ37838448-91E71FBA-0902-4FEF-8FB8-285E268DE803Q38010797-F7FFE2E0-F4DB-4693-B0BB-A88025AECCADQ38068922-E0B78826-3A28-4DB2-9E7B-AFCB00662B64Q38550942-9B19BA8F-CC0E-4653-AF9B-D252ECF21BADQ39109232-6D20F30E-9029-43A3-8AC1-DE3EE2F8E7C3Q39856408-287F453A-8806-4672-AAE5-4C74963CA4A6Q42392542-89B488A1-950B-4F29-92BF-213767D6EA76Q42551794-1445F875-37D1-4D01-9B0D-7982E622C05AQ42603046-13D9B443-D851-4CD5-BE50-CD338DA0B606Q42927138-ACAD2B3A-6852-44D5-A731-0B696E47710AQ45932398-85C1A4F5-D6B2-4AB5-A469-8CBF513C3C52Q46233598-7E2A1B7B-7AA3-4607-B6FC-7862D355C707Q47161748-24007C07-DBD2-41CD-B272-0DFB07D3B00AQ47358265-751B5C84-890E-4C65-B302-7D4787D3B90FQ48094297-C2AE8C57-5DF5-4481-AFAA-DC08FDFC9335Q48279396-7CC41825-6433-4BDB-8555-F36F2827EB3AQ55026900-22388BA4-A797-4BA4-B7D0-9A7D02E62B3C
P2860
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sunitinib and bevacizumab for ...... son of clinical effectiveness.
@en
Sunitinib and bevacizumab for ...... son of clinical effectiveness.
@nl
type
label
Sunitinib and bevacizumab for ...... son of clinical effectiveness.
@en
Sunitinib and bevacizumab for ...... son of clinical effectiveness.
@nl
prefLabel
Sunitinib and bevacizumab for ...... son of clinical effectiveness.
@en
Sunitinib and bevacizumab for ...... son of clinical effectiveness.
@nl
P2093
P2860
P921
P356
P1476
Sunitinib and bevacizumab for ...... son of clinical effectiveness.
@en
P2093
J S Thompson Coon
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605167
P407
P577
2009-06-30T00:00:00Z
2009-07-21T00:00:00Z
P5875
P6179
1013222336